Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults

Biologicals

Volumn 35, Issue 2, 2007, Pages 115-122

  Estévez, Zurina Cinza ^a   Betancourt, Arístides Aguilar ^a   González, Verena Muzio ^a   Baile, Nelvis Figueroa ^a   Silva, Carmen Valenzuela ^b   Bernal, Francisco Hernández ^b,e   Arias, Eduardo Pentón ^a   Fernández, Aurora Delhanty ^c   Olazábal, Nelia Martin ^d   Amaurys del Rio Martin ^b   Batista, Lester Leal ^b   Ríos, Gloria Véliz ^a   Hernández, Héctor Hernández ^a   Hernández, Aracelis Blanco ^d   Lugo, Evelyn Pérez ^d   Joel de la Torre Cruz, ^d   Batista Marchec, Bertha L ^d   Leovaldo Alvarez Falcon ^b   Brito, Jannet Trujillo ^c   León, Darién Ortega ^c   Saura, Pedro López ^b   more..

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Center for Biological Research Cuba   (Cuba)

^c Immunoassay Center Cuba   (Cuba)

^d Playa Municipality   (Cuba)

^e National Center for the Coordination of Clinical Assays   (Cuba)

Author keywords

Clinical trial; Immunogenicity; Recombinant hepatitis B vaccine; Safety

Indexed keywords

HEBERBIOVAC HB; HEPATITIS B SURFACE ANTIGEN; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; BODY MASS; CLINICAL STUDY; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INJECTION SITE ABSCESS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SEX RATIO; VACCINATION; VOMITING;

ADULT; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; SEROLOGIC TESTS; VACCINATION; VACCINES, SYNTHETIC;

EID: 33947321915     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.06.001     Document Type: Article

References (49)

1. Lemon S.M., and Thomas D.L. Vaccines to prevent viral hepatitis. N Engl J Med 16 (1997) 196-204
2. Safary A., and André F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18 (1999) 57-67
3. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 Suppl. 1 (1995) S47-S49
4. Jha R., Lakhtakia S., Narayan G., and Hemlath K. Superior efficacy of Shanvac-B as a Hepatitis B vaccine in dialysis dependent patients. Ind J Nephrol 11 (Oct-Dec 2001) 170-172
5. ul-Haq N., Hasnain S.S., Umar M., Abbas Z., Valenzuela-Silva C., and Lopez-Saura P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine 21 23 (2003 Jul 4) 3179-3185
6. Hardy E., Martinez E., Diago D., Diaz R., Gonzalez D., and Herrera L. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J Biotechnol 77 2-3 (2000 Feb 17) 157-167
7. Gonzalez-Griego Mde J., Cinza Z., Ortega A., Gali M.M., Santoyo M.E., Garcia G., et al. A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine. Rev Cubana Med Trop 50 3 (1998) 218-220
8. Pedroso Flaquet P., Diaz Gonzalez M., Rodriguez Lay L., and Bravo Gonzalez R. The immunogenicity of the Heberbiovac-HB vaccine in the elderly. Rev Cubana Med Trop 48 3 (1996) 200-203
9. Gonzalez-Griego M., Penton E., Delgado G., Perez-Oliva J., Ramos V., Izquierdo M., et al. Impact of an anti-hepatitis B virus (HBV) immunization program in patients undergoing dialysis in Havana, Cuba. Invest Clin 41 4 (2000 Dec) 237-244
10. Shokri F., and Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 19 31 (2001 Aug 14) 4544-4548
11. Diaz Gonzalez M., Navia Molina O., Urbino Lopez-Chavez A., Rodriguez Lay L., Bravo Gonzalez J.R., and Pedroso Flaquet P. Immunogenicity of the Heberbiovac-HB vaccine in doses of 10, 5 and 2.5 micrograms in 6-9-year-old students. Rev Cubana Med Trop 51 1 (1999 Jan-Apr) 46-49
12. Training manual on the critical regulatory functions for vaccines: evaluation of clinical performance through authorized clinical trials. WHO/V&B/03.12 (June 2003). www.who.int/vaccines-documents/
13. Topic Q5E, Step 4 Note for guidance on biotechnological/biological products subject to changes in their manufacturing process (CPMP7ICH/5721/03 final approval by CHMP December 2004). www.emea.eu.int/pdfs/human/ich/572103en.pdf.
14. Guidelines on clinical evaluation of vaccines: regulatory expectations. In: Annex 1. WHO GUIDELINES ON NONCLINICAL EVALUATION OF VACCINES. Adopted by the 54th meeting of the WHO Expert Committee on Biological Standardization, 17-21 November 2003. WHO Technical Report Series No. 924, 2004. www.who.int/biologicals/publications/nonclinical evolution vaccines nov 2003.pdf.
15. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CPMP/BWP/3097/02/final approval by CPMP December 2003). http://www.emea.eu.int/pdfs/human/ewp/309702en.pdf.
16. Guideline on comparability of medicinal product containing biotechnology-derived proteins as active substance: quality issues (EMEA/CPMP/BWP/3201/00/Rev1 2003). http://www.emea.eu.int/pdfs/human/bwp/320700en.pdf.
17. Buenas Prácticas Clínicas. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED) (2000), MINSAP, Cuba. http://www.cecmed.sld.cu/Docs/RegFarm/DRA/EvalDC/Reg/Dir BPC.pdf
18. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964. Amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975; 35th WMA General Assembly, Venice, Italy, October 1983; 41st WMA General Assembly, Hong Kong, September 1989; 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. http://www.seeiuc.com/investig/helsinki.htm.
19. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance (1996), ICH. http://www.fda.gov/cder/guidance/959fnl.pdf
20. Rodríguez L., Balmaseda A., Bravo J., Trujillo J., Martínez L., Ochoa R., et al. Validación de un ultramicroELISA de detección de anticuerpos contra el antígeno de superficie de la hepatitis B. Rev Cubana Med Trop 48 1 (1996) 45-49 enero-abril
21. André F.E. Overview of a five-year clinical experience with a yeast derived hepatitis B vaccine. Vaccine 8 6 (1990) 574-578
22. Engerix-B. Belgium: SmithKline Beecham Pharmaceuticals, 1995 (package insert).
23. Pentón E., Muzio V., and González Griego M. The hepatitis B Virus (HBV) infection and its prevention by a recombinant-DNA viral surface antigen (rec-HBsAg) vaccine. Biotecnología Aplicada 11 1 (1994) 1-11
24. Greenberg D.P. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunization studies. Pedriat Infect Dis J 12 (1993) 438-445
25. Galbán García E., Bravo González J.R., Castañeda Guillot C., Toledo Curbelo G., González Griego A., and Delgado González M.G. Ensayo de campo de la vacuna recombinante cubana contra la hepatitis B. Rev Cubana Med Trop 44 2 (1992) 149-157
26. Díaz M., Chiang A., Díaz D., Bravo J.R., Rodríguez L., Pedroso P., et al. The immunogenicity of the Heberbiovac-HB vaccine in children. Rev Cubana Med Trop 48 3 (1996) 195-198
27. Zajac B.A., West D.J., McAleer W.J., and Scolnick E.M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 13 Suppl. A (1986) 39-45
28. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 303 (1980) 833-841
29. Francis D.P., Halder S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N., et al. Prevention of hepatitis B vaccine: report from the centers for Disease Control multicenter efficacy trial among homosexual men. Ann Intern Med 97 (1982) 362-366
30. Díaz M., Navia O., Bravo J., Pedroso P., and Urbino A. Reactogenicidad de la vacuna HEBERBIOVAC HB a diferentes dosis. Re Cub Med Trop 47 1 (1995) 65-70
31. Jain A., Mathur U.S., Jandwani P., Gupta R.K., Kumar V., and Kar P. A multicentric evaluation of recombinant DNA hepatitis B vaccine of Cuban origin. Trop Gastroenterol 21 1 (2000 Jan-Mar) 14-17
32. Gorbunov M.A., Pavlova L.I., Noslova A.V., Ikoev V.N., Bektimirov T.A., Voitenkov M.M., et al. A comparative evaluation of the immunogenicity and reactogenicity of recombinant vaccines against hepatitis B. Vopr Virusol 38 5 (1993 Sep-Dec) 216-218
33. Heron L.G., Chant K.G., and Jalaludin B.B. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 20 29-30 (2002 Oct 4) 3472-3476
34. Desgrandchamps D., and Siegrist C.A. Vaccination against hepatitis B. Soz Praventivmed 43 Suppl. 1 (1998) S37-S40 S111-4
35. Dienstag J.L., Werner B.G., Polk B.F., Snydman D.R., Craven D.E., Platt R., et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101 1 (1984 Jul) 34-40
36. Young M.D., Gooch III W.M., Zuckerman A.J., Du W., Dickson B., and Maddrey W.C. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination. J Med Virol 64 3 (2001 Jul) 290-298
37. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 31-32 (2002 Nov 1) 3644-3649
38. De Serres G., Duval B., Boulianne N., Rochette M., Dionne M., Fradet M.D., et al. Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. Am J Public Health 91 2 (2001 Feb) 313-315
39. Recommendations and Reports of the ACIP. Update: Vaccine Side Effects, Adverse Reactions, Contraindications, and Precautions. U.S. Department of Health and Human Services vol. 45 (Sep 6, 1996) No. RR-12
40. Philippe Duclos. Safety of immunisation and adverse events following vaccination against hepatitis B. 226. Expert Opin Drug Saf 2 3 (2003) 225-231
41. Honorati M.C., Mariani E., Dolzani P., and Facchini A. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Ist Super Sanita 32 3 (1996) 369-374
42. Marinho R.T., Pedro M., Ramalho F., Velosa J., and De Moura M.C. Vaccine against hepatitis B. Eight years of experience. Acta Med Port 11 11 (1998 Nov) 971-977
43. Clements M.L., Miskovsky E., Davidson M., Cupps T., Kumwenda N., Sandman L.A., et al. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or preS2 + S antigens. J Infect Dis 170 3 (1994) 510-516
44. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., and Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health workers. JAMA 270 (1993) 2935-2939
45. Tolosa N., Tenias J.M., Perez B., and Bautista J. Factors associated with inadequate response to hepatitis B vaccination in health care personnel. Rev Esp Salud Publica 72 6 (1998 Nov-Dec) 509-515
46. Shaw Jr. F.E., Guess H.A., Roets J.M., Mohr F.E., Coleman P.J., Mandel E.J., et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 7 5 (1989) 425-430
47. Havlichek Jr. D., Rosenman K., Simms M., and Guss P. Age-related hepatitis B seroconversion rates in health care workers. Am J Infect Control 25 5 (1997 Oct) 418-420
48. Rosman A.S., Basu P., Galvin K., and Lieber C.S. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 103 3 (1997 Sep) 217-222
49. Weber D.J., Rutala W.A., Samsa G.P., Santimaw J.E., and Lemon S.M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254 (1985) 3187-3189